{"id":"tgrx-326","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of diabetic ketoacidosis"}]},"_chembl":{"chemblId":"CHEMBL3667375","moleculeType":"Small molecule","molecularWeight":"418.47"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, TGRX-326 reduces glucose reabsorption in the kidneys, thereby lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.","oneSentence":"TGRX-326 is a small molecule that targets the SGLT2 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:38:11.642Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT05955391","phase":"PHASE2","title":"TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shenzhen TargetRx Co., Ltd.","startDate":"2023-01-18","conditions":"Non-small Cell Lung Cancer","enrollment":164},{"nctId":"NCT06082635","phase":"PHASE3","title":"TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shenzhen TargetRx Co., Ltd.","startDate":"2023-12-14","conditions":"Non Small Cell Lung Cancer","enrollment":321},{"nctId":"NCT05441956","phase":"PHASE1","title":"TGRX-326 Chinese Phase I for Advanced Non-small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shenzhen TargetRx Co., Ltd.","startDate":"2021-04-23","conditions":"Non-small Cell Lung Cancer","enrollment":198},{"nctId":"NCT06304805","phase":"PHASE1","title":"TGRX-326 Pharmacokinetic Food Effect Bioavailability Study","status":"COMPLETED","sponsor":"Shenzhen TargetRx Co., Ltd.","startDate":"2023-12-13","conditions":"Non Small Cell Lung Cancer","enrollment":24},{"nctId":"NCT06438367","phase":"PHASE1","title":"TGRX-326 Pharmacokinetic Mass Balance","status":"COMPLETED","sponsor":"Shenzhen TargetRx Co., Ltd.","startDate":"2024-06-26","conditions":"Non Small Cell Lung Cancer","enrollment":6},{"nctId":"NCT06294561","phase":"PHASE1","title":"TGRX-326 Pharmacokinetic Drug Interaction","status":"COMPLETED","sponsor":"Shenzhen TargetRx Co., Ltd.","startDate":"2024-03-04","conditions":"Non Small Cell Lung Cancer","enrollment":34}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["TGRX-326 QD (once a day)"],"phase":"phase_3","status":"active","brandName":"TGRX-326","genericName":"TGRX-326","companyName":"Shenzhen TargetRx Co., Ltd.","companyId":"shenzhen-targetrx-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TGRX-326 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}